AzTrials
AzTrials

Post-operative PainPhase 4NCT04182828

Effect of Intravenous Lidocaine on Immediate Post-operative Pain, Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Placebo Controlled Trial

A Phase 4 study testing Lidocaine in people with Post-operative Pain and Post-operative Nausea and Vomiting, run by Aga Khan University Hospital, Pakistan at 1 site in Pakistan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Lidocaine is a drug that has multiple uses. One of these is that when intravenously administered it is effective in reducing post-operative pain. The aim of this study is to investigate the beneficial effects of intravenous lignocaine on reducing pain, nausea and vomiting after laparoscopic cholecystectomy. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Lidocaine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 sitePakistan
Study dates
25 Nov 2019to 24 Nov 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Elective laparoscopic cholecystectomy
  • All adults aged between 18 to 65 years
  • ASA I and II

Who cannot join

  • BMI greater than 35kg/m2
  • Allergy to local anesthetic agents
  • Patient with or history of arrhythmias
  • Patients with SGPT greater than 35 IU/L for females and greater than 45 IU/L for males.
  • Patients with chronic renal disease and creatinine greater than 1.5mg/dl.
  • Chronic use of opioids
  • The surgeries which were converted to open procedures.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site, 1 recruiting
  • Aga Khan University Hospital

    Karachi, Sindh, 74800

    Dr. M. Umer Slote, MBBS, 0092-3333094346 ext. 4637, umerslote_786@hotmail.com

    Dr. Faisal Shamim, FCPS, 0092-21-34864253 ext. 4253, faisal.shamim@aku.edu

    Recruiting

Other trials in Pakistan

About this study

Lidocaine is a drug that has multiple uses. One of these is that when intravenously administered it is effective in reducing post-operative pain. The aim of this study is to investigate the beneficial effects of intravenous lignocaine on reducing pain, nausea and vomiting after laparoscopic cholecystectomy. Also, by this research, we are aiming to find a suitable alternative analgesic.

Read the detailed description

After approval of synopsis from College of Physician and Surgeons of Pakistan (CPSP) and Ethical review committee (ERC) of Aga Khan University Karachi, patients fulfilling the inclusion criteria will be enrolled in the study. Written informed consent will be obtained before the surgery. Patients will be randomly allocated by CTU through computer generated block randomization into either lidocaine group (LG) or placebo group (PG).

The clinical trial unit (CTU) will be responsible to prepare the study drug and placebo in the same volume, color, consistency and packaging and treatment allocation would be done by assigning the study drug and placebo numbers. The staff, patient and the anaesthetists will be blind by the drug allocation. Only the CTU will have the list of randomization and their treatment allocation.

All patient will be given general anesthesia as per standard of care. All patients will be pre-medicated with oral midazolam 7.5 mg one hour before operating room. Standard American Society of Anaesthesiologists (ASA) monitoring (NIBP, ECG, and Pulse Oximetry) will be applied. General anesthesia will be induced by Propofol 2 mg/kg, Nalbuphine 0.1mg/kg and Cis-Atracurium 0.2 mg/kg. Isoflurane 1% - 1.5% in a mixture of oxygen and air (50:50) will be used for maintenance of anesthesia. Before tracheal intubation, patients will receive intravenous bolus injection of the study drug in dose of 1.5mg/kg followed by the continuous infusion at the rate of 1.5mg/kg/hr. via standard computerized programmable infusion pump. The infusion will be continued throughout the surgery and will be stopped after extubation. After intubation, patients' minute ventilation will be adjusted to maintain normocapnia (end tidal CO2 35 - 40 mm of Hg). All patients will be given 1gm of intravenous Paracetamol after induction of anaesthesia. Supplemental analgesia, Nalbuphine 1mg, during surgery will be given if the heart rate and systolic blood pressure increases above 20% of respective baseline values and causes other than pain had been ruled out, which would be at the discretion of the primary anaesthetist. Prophylaxis for nausea and vomiting will be given by Dexamethasone 0.1mg/kg at induction of anaesthesia and Ondansetron 0.1mg/kg after the removal of gall bladder. At the end of surgery, residual neuromuscular blockade will be reversed by 0.05mg/kg of neostigmine and 0.5mg of glycopyrolate. The trachea will be extubated once the patient regained consciousness and then transferred to the post anesthesia care unit (PACU).

In the PACU, each patient will be assessed by the primary investigator for pain, nausea and vomiting at 15, 30, and 60 minutes. If the patient's pain will be equal to 4 or more on the numerical rating scale, he/she will be given Nalbuphine 1mg as a rescue analgesic. Likewise, if the patients has complain of nausea or vomiting, equal to or greater than 2 on Bellvile nausea score, he/she will be given Metoclopramide 10mg as rescue antiemetic. The analgesic and anti-emetic requirement in the ward for the first 6 hr. post-operatively will be recorded by the primary investigator.

The time of arrival at PACU will be recorded as "T1". The discharge time from PACU will also be recorded and would be declared as "T2". The time required for the patient to be discharged from the hospital will be recorded as "TD". TD will be the time when surgical team decides that patient can be discharged from the hospital. The difference between the length of stay in the hospital between the two groups will be calculated as total time spent (in HOURS) in the hospital "TT". It will be the sum of time interval between T1 to T2, and T2 to TD.

TT= (T1+T2+TD)

Being tested
Lidocaine
Medical subject headings
Pain, Postoperative, Vomiting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LidocaineDrug

    Also called Normal saline 0.9%

    both the drugs will be prepared in same volume, color, consistency and appearance

Study groups in NCT04182828
Study groupRoleWhat they receive
Placebo Group(PG)Placebo comparatorIt will be normal saline 0.9%
Receives: Drug: Lidocaine
Lidocaine Group(LG)Active comparatorIt will be lidocaine 2%
Receives: Drug: Lidocaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-operative pain as assessed on numerical rating scale

    Immediate pain after laparoscopic cholecystectomy

    Measured: upto 6 hours

  2. Post-operative nausea and vomiting as assessed on Bellville nausea score

    feeling of nausea and vomiting after laparoscopic cholecystectomy

    Measured: upto 6 hours

Secondary outcomes (1)
  1. Discharge time

    discharge from hospital

    Measured: upto 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2019
  2. Study start25 Nov 2019
  3. Primary completion24 Nov 2020 (estimated)
  4. Study completion24 Nov 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04182828
Sponsor's protocol ID
2019-1558-5378
Status last verified
Dec 2019
First submitted
26 Nov 2019
Last updated
3 Dec 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Lidocaine in people with Post-operative Pain and Post-operative Nausea and Vomiting, run by Aga Khan University Hospital, Pakistan at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Dr. M. Umer Slote, MBBS (0092-3333094346 ext. 4637, umerslote_786@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-operative pain as assessed on numerical rating scale (time frame: upto 6 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in